N. Gabrail

1.3k total citations
32 papers, 924 citations indexed

About

N. Gabrail is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, N. Gabrail has authored 32 papers receiving a total of 924 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in N. Gabrail's work include Cancer Treatment and Pharmacology (13 papers), Lung Cancer Treatments and Mutations (11 papers) and Multiple Myeloma Research and Treatments (6 papers). N. Gabrail is often cited by papers focused on Cancer Treatment and Pharmacology (13 papers), Lung Cancer Treatments and Mutations (11 papers) and Multiple Myeloma Research and Treatments (6 papers). N. Gabrail collaborates with scholars based in United States, Canada and Netherlands. N. Gabrail's co-authors include Gerald V. Doyle, Steven J. Cohen, Cornelis J.A. Punt, Edith P. Mitchell, Nicholas Iannotti, Kert D. Sabbath, Neal J. Meropol, Joel Picus, Michael A. Morse and H. Tissing and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

N. Gabrail

32 papers receiving 897 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N. Gabrail United States 14 569 309 288 221 112 32 924
Chiara Spadazzi Italy 22 612 1.1× 224 0.7× 424 1.5× 363 1.6× 177 1.6× 53 1.2k
Diane Tseng United States 11 701 1.2× 161 0.5× 417 1.4× 275 1.2× 86 0.8× 21 1.5k
Luigi Portella Italy 18 554 1.0× 201 0.7× 353 1.2× 364 1.6× 54 0.5× 30 1.0k
Ivan Ischenko Germany 19 507 0.9× 269 0.9× 621 2.2× 140 0.6× 63 0.6× 22 1.2k
Cristina Nieto‐Jiménez Spain 16 464 0.8× 137 0.4× 456 1.6× 139 0.6× 64 0.6× 40 942
Jane Rabbitt United States 17 257 0.5× 290 0.9× 437 1.5× 474 2.1× 77 0.7× 29 1.5k
Jingcao Huang China 16 369 0.6× 180 0.6× 515 1.8× 111 0.5× 83 0.7× 51 907
Tara Elisabeth Seery United States 12 938 1.6× 344 1.1× 377 1.3× 209 0.9× 96 0.9× 44 1.3k
Hannah K. Brown United Kingdom 21 749 1.3× 355 1.1× 526 1.8× 336 1.5× 108 1.0× 24 1.3k
Bizhan Bandarchi Canada 14 422 0.7× 214 0.7× 440 1.5× 202 0.9× 95 0.8× 19 929

Countries citing papers authored by N. Gabrail

Since Specialization
Citations

This map shows the geographic impact of N. Gabrail's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Gabrail with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Gabrail more than expected).

Fields of papers citing papers by N. Gabrail

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Gabrail. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Gabrail. The network helps show where N. Gabrail may publish in the future.

Co-authorship network of co-authors of N. Gabrail

This figure shows the co-authorship network connecting the top 25 collaborators of N. Gabrail. A scholar is included among the top collaborators of N. Gabrail based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Gabrail. N. Gabrail is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pothuri, Bhavana, et al.. (2024). P2.10A.01 Phase 2 Study of Disitamab Vedotin in Patients with HER2-Expressing Non-Small Cell Lung Cancer (DV-005; Trial in Progress). Journal of Thoracic Oncology. 19(10). S243–S243. 1 indexed citations
2.
3.
Gabrail, N., Dipesh Uprety, Julia Rotow, et al.. (2022). 22P EMB-01: An EGFR-cMET bispecific antibody, in advanced/metastatic solid tumors phase I results. Annals of Oncology. 33. S39–S40. 12 indexed citations
4.
Smith, C., Ronald Yanagihara, Marek Spaczyński, et al.. (2015). Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials. Cancer Management and Research. 7. 83–83. 14 indexed citations
5.
6.
Taylor, Donald R. & N. Gabrail. (2012). Fentanyl Pectin Nasal Spray for Breakthrough Cancer Pain. Future Oncology. 8(2). 121–130. 29 indexed citations
7.
Stewart, A. Keith, Andrzej Jakubowiak, Sundar Jagannath, et al.. (2011). The effect of carfilzomib (CFZ) in patients (Pts) with bortezomib (BTZ)-naive relapsed or refractory multiple myeloma (MM): Updated results from the PX-171-004 study.. Journal of Clinical Oncology. 29(15_suppl). 8026–8026. 5 indexed citations
8.
9.
Wen, Patrick Y., Jan Drappatz, Andrew Brenner, et al.. (2011). Abstract B49: GRN1005 phase I studies: Final results.. Molecular Cancer Therapeutics. 10(11_Supplement). B49–B49. 1 indexed citations
10.
11.
Riely, Gregory J., Scott Gettinger, N. Gabrail, et al.. (2011). Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 29(15_suppl). 7516–7516. 8 indexed citations
12.
Singer, Jack W., Robert Z. Orlowski, Melissa Alsina, et al.. (2010). Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM).. Journal of Clinical Oncology. 28(15_suppl). 8029–8029. 8 indexed citations
13.
14.
Cohen, Steven J., Cornelis J.A. Punt, Nicholas Iannotti, et al.. (2009). Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Annals of Oncology. 20(7). 1223–1229. 418 indexed citations
15.
Kurzrock, Razelle, N. Gabrail, Stacy L. Moulder, et al.. (2009). Abstract B168: ANG1005: Results of a phase I study in patients with advanced solid tumors and metastatic brain cancer. Molecular Cancer Therapeutics. 8(12_Supplement). B168–B168. 1 indexed citations
16.
Bukowski, Ronald M., Walter M. Stadler, Robert A. Figlin, et al.. (2008). Safety and efficacy of sorafenib in elderly patients (pts) ≥65 years: A subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America. Journal of Clinical Oncology. 26(15_suppl). 5045–5045. 17 indexed citations
17.
Batist, Gerald, et al.. (2008). A multicenter, phase II study of CPX-1 liposome injection in patients (pts) with advanced colorectal cancer (CRC). Journal of Clinical Oncology. 26(15_suppl). 4108–4108. 27 indexed citations
18.
Bellet, Robert E., Hassan Ghazal, Marshall S. Flam, et al.. (2007). A phase III randomized controlled study comparing iron sucrose intravenously (IV) to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy. Journal of Clinical Oncology. 25(18_suppl). 9109–9109. 16 indexed citations
19.
Figlin, Robert A., Walter M. Stadler, David F. McDermott, et al.. (2007). The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy. Journal of Clinical Oncology. 25(18_suppl). 5011–5011. 38 indexed citations
20.
Rizvi, Naiyer A., Miguel A. Villalona‐Calero, Timothy Lynch, et al.. (2005). P-565 A Phase II study of KOS-862 (Epothilone D) as second-linetherapy in non-small cell lung cancer. Lung Cancer. 49. S266–S267. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chiara Spadazzi Breakdown of academic impact, for papers by Diane Tseng Breakdown of academic impact, for papers by Luigi Portella Breakdown of academic impact, for papers by Ivan Ischenko Breakdown of academic impact, for papers by Cristina Nieto‐Jiménez Breakdown of academic impact, for papers by Jane Rabbitt Breakdown of academic impact, for papers by Jingcao Huang Breakdown of academic impact, for papers by Tara Elisabeth Seery Breakdown of academic impact, for papers by Hannah K. Brown Breakdown of academic impact, for papers by Bizhan Bandarchi
Rankless by CCL
2026